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PPOpatients compared to other groups. Future analyses should determinewhether
insurance coverage is associated with access to medical care and subsequent clin-
ical and HRQOL outcomes. These results serve as a baseline reference.
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OBJECTIVES: The use of administrative datasets can be a useful tool in cancer
surveillance by providing disease patterns, utilization of services, and patient char-
acteristics. This study explores characteristics of treatment and staging among
lung cancer patients in the US using hospital-based services. METHODS: A cross-
sectional study of chemotherapy treated lung cancer patients receiving in or out-
patient services from hospitals in MedAssets’ health data from July 1, 2010 to June
30, 2011 were assessed for staging and treatment characteristics. The Thomas, et
al. staging algorithm was applied to patient services to estimate stage of lung
cancer. Descriptive statistics were calculated for the sample by stage, treatment
characteristics, procedures and hospital characteristics. Patterns of care were tab-
ulated and compared by cancer stage. RESULTS: The sample included 14,628
unique patients who received chemotherapy during the study period spanning
over 217,000 hospital visits. The majority (75%) of hospital visits were classified as
stage 1-2 compared to stage 3-4 (25%). Stage 1-2 patients experienced fewer hospi-
tal visits (5.9 vs. 12.5, p 0.0001) and had a significantly higher proportion of inpa-
tient stays (22.1% vs. 6.7%, p 0.0001). Most visits (88.7%) occurred in hospital-
based outpatient facilities. There were 52,289 (3.1 visits per patient) chemotherapy
related visits. Primary chemotherapies included: pemetrexed disodium (16.2 %),
carboplatin (34.3%) and cisplatin (11.0%). Blood transfusions and other non-surgi-
cal procedures made up the largest portion (25.4%) of all procedures performed on
both groups. Finally, both groups were treated in primarily in large (300 beds,
75.1%), urban (90.1%), and teaching (59.1%) hospitals. CONCLUSIONS: The cross-
sectional analysis demonstrates the possible value of large-scale administrative
data sets in illuminating differences in treatment characteristic in a chemothera-
py-treated lung cancer population. Future analysis should evaluate the use of these
data to help predict utilization and treatment patterns in larger populations.
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LINES OF SYSTEMIC THERAPY IN PATIENTS WITH METASTATIC MELANOMA
IN THE UNITED STATES
Zhao Z, Wang S, Barber B, Wagner V
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OBJECTIVES: To describe treatment patterns by lines of systemic (drug) therapy in
patients with metastatic melanoma in the United States.METHODS: Using a large
USmedical claims database, patients were identified between 2005 and 2010 using
2 melanoma diagnoses (ICD-9-CM: 172.xx, V10.82) and 2 diagnoses for metas-
tasis (ICD-9-CM: 197.xx, 198.xx). Patients were followed from the metastatic diag-
nosis date to death, disenrollment, or end of study period (6/30/2010), whichever
occurred first. Lines of systemic therapy were identified based on the temporal
order, gaps, and changes in the drug regimens. Systemic therapies and the dura-
tion of therapy in each line were examined. RESULTS: A total of 2546 patients with
metastaticmelanomawere included and 985 (38.7%) received systemic therapy. As
the first documented therapy after diagnosis, 82.4% of patients received mono-
therapy (38.5% temozolomide, 14.3% interleukin-2, 11.4% interferon alfa-2b, 8.2%
dacarbazine, 2.9% paclitaxel, 2.5% GM-CSF) and 9.4% received carboplatin plus pa-
clitaxel. Mean duration of mono-therapy was 60 days, ranging from 32 days on
interleukin-2 to 124 days on GM-CSF. Of 287 patients (29.1% of previously treated)
received subsequent therapy, 68.0% received mono-therapy (26.8% temozolomide,
11.9% interleukin-2, 10.5% dacarbazine, 8.4% paclitaxel, 3.1% interferon alfa-2b,
1.7% GM-CSF), 16.7% carboplatin plus paclitaxel, and 7.3% dacarbazine-containing
therapies. Mean duration of mono-therapy was 67 days, ranging from 30 days on
interleukin-2 to 238 days on GM-CSF. Among 71 patients who further received
additional therapy, mono-therapy was still the dominant regimen (63.4%) with
21.1% temozolomide, 18.3% paclitaxel, 8.5% interleukin-2, 5.6% dacarbazine, 4.2%
GM-CSF, and 1.4% interferon alfa-2b. Carboplatin plus paclitaxelwas given to 19.7%
of patients. Mean duration of mono-therapy was 63 days, ranging from 7 days on
interferon alfa-2b to 90 days on temozolomide. CONCLUSIONS: The majority of
patients with advanced melanoma didn’t receive systemic therapy as captured in
the claims database; among those who received systemic therapy, mono-therapy
was most common.
PCN145
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OBJECTIVES: To identify treatment patterns of care in patients with unresectable
stage III or stage IV melanoma disease in three public hospitals in Mexico.
METHODS: Retrospective longitudinal study that includes 102 adult patients with
unresectable stage III (any T, N1, M0) or stage IV (any T, any N, M1) melanoma,
diagnosed and treated from 2007 to 2010, at three specialty public hospitals in
Mexico (Centro Médico Nacional Siglo XXI, Hospital General de Mexico and Insti-
tuto Nacional de Ciencias Médicas y Nutrición). Patient characteristics and re-
source utilization were reported for each stage of treatment (diagnosis, first line
treatment, and second line or palliative care) and includes consultations, labora-
tory tests, hospitalization, surgery, hematologic support, radiotherapy and sys-
temic treatment. RESULTS: The mean age at time of diagnosis was 60.44 years old
CI(56.88-64.00) and a men-women ratio of 1.17:1, 86% in clinical stage III and 14%
stage IV. The total cost of diagnosis was $15,628.10 CI($9,329.07-$21,927.14), which
includes: consultations $4,225.96 CI($3,423.20-$5,028.72), laboratory tests $5,930.40
CI($3,768.31-$8,092.49), and hospitalizations $5,471.74 CI($1,188.12-$9,755.37). Dur-
ing first line treatment, 44.9% of all cases report hospitalization, 21.8% radiother-
apy, 69.2% surgery and 76.9% systemic therapy (Dacarbazine 28.8%, Interferon-
66.1% and Temozolomide 5.1%), with a total cost of $76,162.57 ($64,771.54-
$87,553.59). Only 37.2% report a second line treatment, with a mean cost of
$25,816.83 CI($21,638.70-$29,994.97), the systemic treatment (monotherapy or
combined) included CDDP 11.5%, Dacarbazine 61.5%, Interferon- 19.2%, Paclitaxel
11.5%, Carboplatin 3.8% and Vinorelbine 3.8. CONCLUSIONS: In this study, 76.9% of
the patients received first line systemic treatment, and only 37.2% received a sec-
ond line active treatment or palliative care. The lack of active treatment could be
associated with a poor performance status in these patients, as well as a lack of
availability of effective drugs for the treatment of unresectable stage III or stage IV
melanoma in the public Mexican hospitals.
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OBJECTIVES: To explore physician specialty patterns for the treatment of hepato-
cellular carcinoma (HCC). METHODS: Medicare patients diagnosed with HCC in
2000-07 with1 claim for HCC-related physician visits post-diagnosis were stud-
ied through 2009 using SEER-Medicare data. Transplant patients were excluded.
Visits by specialists seenwithin 4weeks of diagnosis and by therapywithin the first
treatmentweekwere explored. Specialties: Gastroenterology (GE), General/Family/
Geriatric/Internal (GF), Diagnostic/Intervention radiology (DIR), Hematology/Med-
ical oncology (HMO), General surgery/Surgery oncology (GSO), Radiation oncology
(RO), Multispecialty clinic/group practice (MG), Others. Therapies (non-mutually
exclusive): surgical resection, percutaneous ablation, transarterial chemoemboli-
zation (TACE), bland embolization, systemic chemotherapy, selective internal ra-
diation therapy, external beam radiation therapy. We examined second-line ther-
apy, specialists seen since week 5, and multiple-specialty visits as related to
multiple-first-line therapies. RESULTS: Of 6472 patients with1 specialist, 25%
saw GE, 10.5%GF, 23% DIR, 28%HMO, 16% GSO, 4% RO, 5.5%MG, and 66%Other; 52%
saw1 specialist type within 4 weeks of diagnosis, 5%none until after 4 weeks; 6%
had a resection as first line, 8%ablation, 9%TACE, 0.7%TAE, 9%chemo, 1%SIRT,
8%EBRT; 64% were untreated; 46% of patients saw only 1 specialist type in the first
4 weeks and 4% got 1 therapy form in the first treatment week. The specialties
distributions did not differ across first-line therapies. Other specialists were seen
by 65% of patients. GE and HMO were the most common specialty: 21-29% of pa-
tients sawGE and 23-37% sawHMO, 20-24%DIR, 11-17%GSO, 9-13%GF, 4-6%RO, and
1%MG, across therapies. Of the 2819 patients who saw only 1 type of specialist in
the first 4 weeks, 52% visited Others, 13%GE, 11%HMO, 10%DIR, 6%GSO, 5%GF,
4%RO, and 0.4%MG. CONCLUSIONS: HCC patients commonly see Gastroenterolo-
gists and Hematologists/Medical oncologists within 4 weeks of HCC diagnosis.
There was no clear HCC treatment pattern by specialist type.
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OBJECTIVES: Observational data of chronic myelogenous leukemia (CML) patients
is difficult to obtain outside of a randomized clinical trial (RCT) setting. A retrospec-
tive research registry was developed to evaluate the outcomes of CML treatment
decisions.METHODS: The CML cohort was created through amaster patient index
(MPI) across the Huntsman Cancer Institute, University Hospital, and Outpatient
Clinics. Patient records (1995 – 2010) were included with CML ICD-9 codes (250.1,
205.10-12); age  18; a listing in the Utah Population Database; and chart review,
including physician notes and laboratory results, indicative of CML. RESULTS: A
total of 234 patients had confirmed CML (140 males, 59.8%). Mean age at diagnosis
was 46 (SD 15.1). Of those, 211 subjects (90.2%) were diagnosed in chronic phase
(CP), 12 (5.1%) in accelerated phase and 5 (2.1%) in blast phase (BP) with 15.5 (me-
dian; 14.6 mean, SD 4.2) CML cases diagnosed per year. Baseline lab results and
comorbidity scores were not statistically significantly different by stage, except for
an elevated platelet count in BP (p0.01). First line treatment was a tyrosine kinase
inhibitor for 51.3% overall, and 77.1% in new cases from 2001. Bone marrow trans-
plantwas utilized in 16.7%of patients overall. After 10 years, overall survival for the
CML cohort was 59.5%. Overall survival was 84.8% for patients diagnosed in CP and
treated with imatinib, 63.1% for patient’s receiving BMT and 41.4% for patients
treated with interferon-alpha. The most common cause of death overall was CML
(45.1%); in those receiving imatinib 38.9% died from CML. CONCLUSIONS: Clinical
outcomes data integrated via a MPI across a comprehensive research database to
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complement RCT data and prospective patient registries for the evaluation of con-
temporary practice including biomarkers used for diagnosis, treatment decisions
and prognosis in the management of CML patients.
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OBJECTIVES: The consideration of subgroup analyses is an emerging topic in
health care evaluation. With value-for-money being an important issue, alongside
the question “is this therapy effective?”, another question becomingmore relevant
is “in whom is this therapy effective?” This issue is particularly relevant to the
development of cancer treatments, which are often expensive and indicated in
small patient populations. The use of personalised medicine is therefore expected
to play a large role in this disease area. The aimof this studywas to investigate how
the proportion of cancer trials taking personalised medicine into account has
changed over time. METHODS: ClinicalTrials.gov was searched for all interven-
tional cancer trials that considered the use of individualised medicine, by using
search terms including ‘diagnostic’, ‘prognostic’ and ‘biomarker’. Search results
were de-duplicated, and the start dates of these trialswere analysed and compared
to those of all interventional cancer trials listed on ClinicalTrials.gov. RESULTS: In
total, 2810 cancer trials considered personalised medicine. The distribution of
thesewas strongly skewed towards recent years,with only 57 of the trials identified
having started before 2000. Across all cancer trials, 2.5%of those started before 2000
considered personalised medicine, whereas this percentage increased to 13.6%
after this date. Interestingly, 20.6% of cancer trials commencing in 2010, compared
to 17.0% of those in 2011, involved individualised medicine, indicating that there
might be a slight decline in the investigation of personalised medicine recently.
Trials considering individualised medicine were most often conducted in the
United States or Europe, and in disease areas such as leukaemia, head and neck,
brain, and prostate cancer. CONCLUSIONS: Personalised medicine has started to
play a bigger role in cancer therapy development since the year 2000. With the
current health care market focusing on value-for-money, however, it is surprising
that only one-fifth of recent trials considered this issue.
PCN149
TRANSFERABILITY OF PHARMACOECONOMIC EVALUATIONS: CASE STUDY OF
TRASTUZUMAB FOR EARLY BREAST CANCER
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OBJECTIVES:Using a simplemethodwe determined the potential transferability of
a previous economic evaluation on the cost effectiveness of adjuvant trastuzumab
therapy for the treatment ofHER2/Neu-positive breast cancer in Canada (Skedgel et
al, 2009) to five other countries (UK, US, Australia, Japan and Germany).METHODS:
Based on data from a literature review, we firstly identified all possible transfer-
ability factors. From this we selected key transferability factors – those with values
that differed across the countries or were factors that were shown to influence the
cost-effectiveness ratio in sensitivity analysis in the Canadian reference study.We
then considered the ease of transferability (ranging from very low to very high) for
each of these potential factors from the Canadian study to the other countries.
RESULTS: We identified seven potential key factors for transferability: cost dis-
count rate, health outcomes discount rate, unit costs (particularly drug acquisition
cost), resources used, treatment effectiveness, (including duration of benefit) and
measures used to determine utility values. Overall, potential transferability was
highest for the UK, where treatment practice is similar to that in Canada and data
on unit costs, resource use and discount rates are readily available. Because the
authors of the reference study did not report unit costs and resource use sepa-
rately, however, transferability of the analysis was hindered. Transferability to
Australia, Germany and the United States was of an intermediate level, while
transferability to the Japanese settingwas the lowest because treatment practice is
likely to be different, and little cost of illness and utility data exist for that country.
CONCLUSIONS: Several key factors need to be considered when evaluating
whether a study is transferable to another setting. To enable the transferability of
economic evaluations from one country to another, authors need to ensure that
they report their economic data clearly and in sufficient detail.
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OBJECTIVES: Pooling annual data together from the Medical Expenditure Panel
Survey (MEPS) is legitimate way to produce average annual estimates based on
“person-years” for any condition. AHRQ state that over 100 cases are required in
order to do this. The objective of this study is to look at the direct medical costs
associated with head and neck cancer (HNC) using this data source. METHODS:
MEPS data was pooled (2003-2008) and analyzed for respondents with HNC (CCS
code11). Two different approaches were used. Consolidated year files and condi-
tion files were pooled together to calculate estimates on use and expenditures for
persons with HNC (condition approach). Yearly event files were used to pool con-
dition-event files to establish an attributable fraction approach. Both approaches
inflated expenditure data to 2008 USD. RESULTS: A total of 120 respondents were
identified to have a diagnosis of HNC when data was pooled. The condition ap-
proach estimated that the national yearly expenditures of HNC is in the order of
$16.47bn with mean spend of $14,573 (SE$2,227) per case per year. The attribut-
able fraction approach estimated that expenditures for all events associated with
HNC are significantly less - $8.49bn with a mean of $4788 (SE$1,057) per case per
year. There were only 103 cases that had an event associated with the condition.
Private payors accounted formost expenditure, though the proportionwas slightly
lower using the condition approach (46% vs. 56%). The analysis noted that attrib-
utable expenditures were driven by ambulatory visits where condition expendi-
tures were driven by inpatient costs. CONCLUSIONS: MEPS is often used to esti-
mate the direct medical costs of a condition. This analysis illustrates that for rare
cases, such as HNC, that both approaches offer insight into characterizing a con-
dition. Subsequently, a range for cost estimates can be determined using this data
source.
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OBJECTIVES: Determining which economic and health resource utilization data
points to collect in clinical trials requires a balance between comprehensiveness
and data collection burden. Cost and time constraints necessitate that only the
most critical economic variables be collected. Our objectivewas to test the utility of
a new tool for determining the most frequent types and timing of healthcare uti-
lization among cancer patients in a quick and low cost manner. METHODS: We
used an online interactive data analysis tool, MarketScan®Treatment Pathways, to
explore the most frequent adverse events (AE) and their related healthcare utiliza-
tion patterns in a sample of non-small cell cancer patients (NSCLC). Patientswith at
least 2 ICD-9 codes for lung cancer on different dayswithin 30 days of each other on
non-rule out claims and no chemotherapies associatedwith small-cell lung cancer
were included. The subset of patients with a diagnosis for metastatic cancer fol-
lowing their NSCLC diagnosis who received at least one oral or injectible chemo-
therapy treatment were analyzed. RESULTS: 5,243 patients withmetastatic NSCLC
were identified, of whom 2,006 received at least one oral or injectible treatment.
80% of experienced at least one AE serious enough to require healthcare interven-
tion. Themedian andmean days to the first AEwere 20 and 51.5 days from the time
of the first treatment. Themost commonAEswere anemia (51.2%), gastrointestinal
events (34.8%), fatigue (26.1%), and neutropenia (24.2%). Of those with anemia, 36%
received epoetin or darbepoetin alpha and of thosewith neutropenia, 77% received
pegfilgrastim or filgrastim. Additional patient clinical and treatment characteris-
tics were described for the 30 days following each AE. Total analysis time for this
project was under 3 hours. CONCLUSIONS: Treatment Pathways answered critical
questions for the design of economic endpoint data collection for a new cancer trial
in just a few hours.
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OBJECTIVES: To assess the societal value of a prospective randomized clinical trial
(RCT) for breast tumor marker testing in routine follow-up of high-risk, stage II-III
breast cancer survivors. METHODS: We used value of information techniques to
assess the benefits of reducing uncertainty of using breast cancer tumor markers.
We developed a decision-analytic model of biomarker testing in addition to stan-
dard surveillance at follow-up appointments every 3-6 months for five years. Ex-
pected value of sample information (EVSI) was assessed over a range of trial sizes
and assumptions. RESULTS: The overall value of research for an RCT involving
9000 women was $166 million (EVSI). The value of improved information charac-
terizing the survival impact of tumor markers was $81 million, quality-of-life $38
million, and test performance $95 million. CONCLUSIONS: Despite not being rec-
ommended by clinical guidelines, the tumor markers carcinoembryonic antigen
(CEA), cancer antigen (CA)15-3, and CA 27.29 are used by some clinicians to screen
for increased risk of breast cancer recurrence. Although additional researchmay be
warranted to evaluate the benefits and risks of breast cancer tumor marker tests,
clinical trials would likely need to involve thousands of women and would take
many years to complete. Our analysis indicates that substantial societal valuemay
be gained by conducting a clinical trial evaluating the use of breast cancer tumor
markers. The most important aspects of the trial in our analysis were information
gained on survival improvements as well as quality-of-life parameters associated
with testing and test sensitivity and specificity. Our analysis indicates that smaller
randomized trials, as well as adding quality of life instruments to existing trials,
retrospective, and observational trials can also generate valuable and relevant in-
formation.
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CHALLENGES POSED BY PATIENT CROSSOVER FOR COST-EFFECTIVENESS
ANALYSIS OF ONCOLOGY PRODUCTS: A CASE STUDY IN METASTATIC
PANCREATIC CANCER
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